CureVac (NASDAQ:CVAC) Reaches New 12-Month Low – Here’s What Happened

CureVac N.V. (NASDAQ:CVAC) reached a new 52-week low during trading on Monday . The stock traded as low as $4.01 and last traded at $4.0650, with a volume of 576889 shares changing hands. The stock had previously closed at $4.16.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of CureVac in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.83.

CureVac Price Performance

The business’s fifty day moving average price is $5.15 and its 200 day moving average price is $5.30. The stock has a market cap of $968.02 million, a P/E ratio of 5.99 and a beta of 1.77. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.70 and a quick ratio of 3.69.

CureVac (NASDAQ:CVAC) last posted its earnings results on Monday, November 24th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. CureVac had a net margin of 199.92% and a negative return on equity of 23.03%. The firm had revenue of $63.53 million for the quarter, compared to analyst estimates of $21.40 million. Sell-side analysts forecast that CureVac N.V. will post 0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Qube Research & Technologies Ltd grew its holdings in shares of CureVac by 44.9% in the third quarter. Qube Research & Technologies Ltd now owns 1,712,737 shares of the company’s stock valued at $9,232,000 after acquiring an additional 530,686 shares in the last quarter. Bank of America Corp DE increased its position in shares of CureVac by 364.4% during the 3rd quarter. Bank of America Corp DE now owns 443,324 shares of the company’s stock valued at $2,390,000 after purchasing an additional 347,854 shares during the last quarter. AQR Arbitrage LLC raised its stake in shares of CureVac by 2,145.7% during the 3rd quarter. AQR Arbitrage LLC now owns 991,688 shares of the company’s stock worth $5,345,000 after purchasing an additional 947,529 shares during the period. Amundi boosted its holdings in shares of CureVac by 34.4% in the 3rd quarter. Amundi now owns 183,856 shares of the company’s stock worth $995,000 after buying an additional 47,060 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in CureVac by 95.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 57,286 shares of the company’s stock valued at $309,000 after buying an additional 28,033 shares during the period. Hedge funds and other institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.